Development of novel arginase inhibitors for therapy of endothelial dysfunction

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Steppan, Jochen ^a   Nyhan, Daniel ^a   Berkowitz, Dan E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Arginase; Diabetes mellitus; Endothelial dysfunction; Endothelium; L arginine; Nitric oxide synthase; Reactive oxygen species

Indexed keywords

(R) 2 AMINO 6 BORONO 2 (2 (PIPERIDIN 1 YL)ETHYL)HEXANOIC ACID; 2(S) AMINO 6 BORONOHEXANOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLCHOLINE; AMINO ACID TRANSPORTER; ARGINASE 1; ARGINASE 2; ARGINASE INHIBITOR; CITRULLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; N HYDROXY GUANIDINIUM; N HYDROXY L ARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEPTIDES AND PROTEINS; PICEATANNOL 3' O B D GLUCOPYRANOSIDE; REACTIVE OXYGEN METABOLITE; S (2 BORONOETHYL) L CYSTEINE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; X RAY CRYSTALLOGRAPHY;

EID: 84885963273     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00278     Document Type: Review

References (55)

1. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch (2000) 440(5):653-66. doi:10.1007/s004240000307.
2. Woodward JJ, Chang MM, Martin NI, Marletta MA. The second step of the nitric oxide synthase reaction: evidence for ferric-peroxo as the active oxidant. J Am Chem Soc (2009) 131(1):297-305. doi:10.1021/ja807299t.
3. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation (2003) 108(16):2000-6. doi:10.1161/01.CIR.0000092948.04444.C7.
4. Steppan J, Ryoo S, Schuleri KH, Gregg C, Hasan RK, White AR, et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci U S A (2006) 103(12):4759-64. doi:10.1073/pnas.0506589103.
5. White AR, Ryoo S, Li D, Champion HC, Steppan J, Wang D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension (2006) 47(2):245-51. doi:10.1161/01.HYP.0000198543.34502.d7.
6. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 110(24):3708-14. doi:10.1161/01.CIR.0000142867.26182.32.
7. Nawrath H, Wegener JW, Rupp J, Habermeier A, Closs EI. Voltage dependence of L-arginine transport by hCAT-2A and hCAT-2B expressed in oocytes from Xenopus laevis. Am J Physiol Cell Physiol (2000) 279(5):C1336-44.
8. Rotmann A, Closs EI, Liewald JF, Nawrath H. Intracellular accumulation of L-Arg, kinetics of transport, and potassium leak conductance in oocytes from Xenopus laevis expressing hCAT-1, hCAT-2A, and hCAT-2B. Biochim Biophys Acta (2004) 1660(1-2):138-43. doi:10.1016/j.bbamem.2003.11.009.
9. Topal G, Brunet A, Walch L, Boucher JL, David-Dufilho M. Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther (2006) 318(3):1368-74. doi:10.1124/jpet.106.103747.
10. Solomonson LP, Flam BR, Pendleton LC, Goodwin BL, Eichler DC. The caveolar nitric oxide synthase/arginine regeneration system for NO production in endothelial cells. J Exp Biol (2003) 206(Pt 12):2083-7. doi:10.1242/jeb.00361.
11. Koga T, Koshiyama Y, Gotoh T, Yonemura N, Hirata A, Tanihara H, et al. Coinduction of nitric oxide synthase and arginine metabolic enzymes in endotoxin-induced uveitis rats. Exp Eye Res (2002) 75(6):659-67. doi:10.1006/exer.2002.2062.
12. Louis CA, Reichner JS, Henry WL Jr, Mastrofrancesco B, Gotoh T, Mori M, et al. Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension. Am J Physiol (1998) 274(3 Pt 2):R775-82.
13. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol (1995) 25(4):1101-4. doi:10.1002/eji.1830250436.
14. Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol (1998) 275(5 Pt 1):E740-7.
15. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 416(6878):337-9. doi:10.1038/416337a.
16. Christianson DW. Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res (2005) 38(3):191-201. doi:10.1021/ar040183k.
17. Ashamiss F, Wierzbicki Z, Chrzanowska A, Scibior D, Pacholczyk M, Kosieradzki M, et al. Clinical significance of arginase after liver transplantation. Ann Transplant (2004) 9(3):58-60.
18. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, et al. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry (2001) 40(9):2678-88. doi:10.1021/bi002317h.
19. Ricky Baggio DE, Kanyo ZF, Carroll PJ, Cavalli C, Ash DE, Christianson DW. Inhibition of Mn2+2-arginase by borate leads to the design of a transition state analogue inhibitor, 2(S)-amino-6-boronohexanoic acid. J Am Chem Soc (1997) 119(34):8107-8. doi:10.1021/ja971312d.
20. Kanyo ZF, Scolnick LR, Ash DE, Christianson DW. Structure of a unique binuclear manganese cluster in arginase. Nature (1996) 383(6600):554-7. doi:10.1038/383554a0.
21. Di Costanzo L, Sabio G, Mora A, Rodriguez PC, Ochoa AC, Centeno F, et al. Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 102(37):13058-63. doi:10.1073/pnas.0504027102.
22. Cama E, Colleluori DM, Emig FA, Shin H, Kim SW, Kim NN, et al. Human arginase II: crystal structure and physiological role in male and female sexual arousal. Biochemistry (2003) 42(28):8445-51. doi:10.1021/bi034340j.
23. Baggio R, Emig FA, Christianson DW, Ash DE, Chakder S, Rattan S. Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor. J Pharmacol Exp Ther (1999) 290(3):1409-16.
24. Cox JD, Kim NN, Traish AM, Christianson DW. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat Struct Biol (1999) 6(11):1043-7. doi:10.1038/14929.
25. Shin H, Cama E, Christianson DW. Design of amino acid aldehydes as transition-state analogue inhibitors of arginase. J Am Chem Soc (2004) 126(33):10278-84. doi:10.1021/ja047788w.
26. Colleluori DM, Ash DE. Classical and slow-binding inhibitors of human type II arginase. Biochemistry (2001) 40(31):9356-62. doi:10.1021/bi010783g.
27. Cama E, Pethe S, Boucher JL, Han S, Emig FA, Ash DE, et al. Inhibitor coordination interactions in the binuclear manganese cluster of arginase. Biochemistry (2004) 43(28):8987-99. doi:10.1021/bi0491705.
28. Boucher JL, Custot J, Vadon S, Delaforge M, Lepoivre M, Tenu JP, et al. N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem Biophys Res Commun (1994) 203(3):1614-21. doi:10.1006/bbrc.1994.2371.
29. Boucher JL, Moali C, Tenu JP. Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci (1999) 55(8-9):1015-28. doi:10.1007/s000180050352.
30. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide (1999) 3(6):427-38. doi:10.1006/niox.1999.0255.
31. Cox JD, Cama E, Colleluori DM, Pethe S, Boucher JL, Mansuy D, et al. Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase. Biochemistry (2001) 40(9):2689-701. doi:10.1021/bi002318+.
32. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation (2012) 126(25):2943-50. doi:10.1161/CIRCULATIONAHA.112.140335.
33. Van Zandt MC, Whitehouse DL, Golebiowski A, Ji MK, Zhang M, Beckett RP, et al. Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury. J Med Chem (2013) 56(6):2568-80. doi:10.1021/jm400014c.
34. Ilies M, Di Costanzo L, Dowling DP, Thorn KJ, Christianson DW. Binding of alpha, alpha-disubstituted amino acids to arginase suggests new avenues for inhibitor design. J Med Chem (2011) 54(15):5432-43. doi:10.1021/jm200443b.
35. Golebiowski A, Paul Beckett R, Van Zandt M, Ji MK, Whitehouse D, Ryder TR, et al. 2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors. Bioorg Med Chem Lett (2013) 23(7):2027-30. doi:10.1016/j.bmcl.2013.02.024.
36. Woo A, Min B, Ryoo S. Piceatannol-3'-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity. Exp Mol Med (2010) 42(7):524-32. doi:10.3858/emm.2010.42.7.053.
37. Kim SW, Cuong TD, Hung TM, Ryoo S, Lee JH, Min BS. Arginase II inhibitory activity of flavonoid compounds from Scutellaria indica. Arch Pharm Res (2013) 36(8):922-6. doi:10.1007/s12272-013-0125-3.
38. Matsuda H, Morikawa T, Toguchida I, Park JY, Harima S, Yoshikawa M. Antioxidant constituents from rhubarb: structural requirements of stilbenes for the activity and structures of two new anthraquinone glucosides. Bioorg Med Chem(2001) 9(1):41-50. doi:10.1016/S0968-0896(00)00215-7.
39. Woo A, Shin W, Cuong TD, Min B, Lee JH, Jeon BH, et al. Arginase inhibition by piceatannol-3'-O-beta-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet. Int J Mol Med (2013) 31(4):803-10. doi:10.3892/ijmm.2013.1261.
40. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol (2000) 130(5):963-74. doi:10.1038/sj.bjp.0703393.
41. Egan JM, Henderson TE, Bernier M. Arginine enhances glycogen synthesis in response to insulin in 3T3-L1 adipocytes. Am J Physiol (1995) 269(1 Pt 1):E61-6.
42. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care (2008) 31(1):134-9. doi:10.2337/dc07-1198.
43. Salimuddin, Upadhyaya KC, Baquer NZ. Effects of vanadate on expression of liver arginase in experimental diabetic rats. IUBMB Life (1999) 48(2):237-40. doi:10.1080/152165499307297.
44. Wu G, Meininger CJ. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol (1995) 269(4 Pt 2):H1312-8.
45. Bjelakovic G, Sokolovic D, Ljiljana S, Kocic G, Jevtovic T, Stojanovic I, et al. Arginase activity and magnesium levels in blood of children with diabetes mellitus. J Basic Clin Physiol Pharmacol (2009) 20(4):319-34. doi:10.1515/JBCPP.2009.20.4.319.
46. Salimuddin, Upadhyaya KC, Raju J, Baquer NZ. Modulation of mRNA levels of liver arginase by insulin and vanadate in experimental diabetes. Indian J Biochem Biophys (1999) 36(2):125-8.
47. Stickings P, Mistry SK, Boucher JL, Morris SM, Cunningham JM. Arginase expression and modulation of IL-1beta-induced nitric oxide generation in rat and human islets of Langerhans. Nitric Oxide (2002) 7(4):289-96. doi:10.1016/S1089-8603(02)00122-2.
48. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation (2002) 105(15):1756-9. doi:10.1161/01.CIR.0000015465.73933.3B.
49. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5.
50. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res (2008) 102(1):95-102. doi:10.1161/CIRCRESAHA.107.155028.
51. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol (2011) 300(3):H777-83. doi:10.1152/ajpheart.00831.2010.
52. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, et al. Macrophage plasticity in experimental atherosclerosis. PLoS ONE (2010) 5(1):e8852. doi:10.1371/journal.pone.0008852.
53. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol (2012) 32(6):463-88. doi:10.1615/CritRevImmunol.v32.i6.10.
54. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis (2010) 30(3):245-57. doi:10.1055/s-0030-1255354.
55. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol (2008) 105(5):1632-42. doi:10.1152/japplphysiol.90627.2008.